Recall: Teva- Bupropion 300mg - lower strength tablet
Brand(s)
Last updated
Summary
Product
TEVA-BUPROPION XL 300MG TABLETS
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Distribution
National
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot numbers |
|---|---|---|---|---|---|
| Teva | TEVA-BUPROPION XL | DIN 02439662 | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300mg | 100055815 & 100061092 |
Issue
Affected lot may contain the presence of a lower strength tablet.
What you should do
- Verify if your product is affected.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
National
Recall class
Type II
Identification number
RA-75907
Get notified
Receive emails about new and updated recall and safety alerts.